Trial Profile
A Randomized, Double-masked, Multicenter, Controlled Dose- and Interval-ranging Clinical Study of Intravitreal Injection of KH902 in Patients With Neovascular Age-related Macular Degeneration (the AURORA Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2019
Price :
$35
*
At a glance
- Drugs Conbercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Acronyms the AURORA study
- Sponsors Chengdu Kanghong Biological Science & Technology
- 01 Sep 2014 New trial record